Table 1.

Sample data

Sample class	Sample Nr.	Sample description/age	CD44+ CRC	EpCam+ CRC
Negative control—healthy	14	Male/55	3	None
	16	Male/41	1	None
	17	Male/39	0	None
	18	Female/36	0	None
	20	Female/39	1	None
	21	Female/50	2	None
	22	Male/33	3	None
	23	Female/36	2	None
	25	Female/39	2	None
	28	Male/41	1	None
		Median	1.5 ± 1.08
Negative control—non-malignant disorder	13	Diabetes type II, insulin treatment, female/55	46	None
	15	Pfizer 1st inoculation 1 week after, female/36	11	None
	19	Mild non-alcoholic fatty liver, male/48	9	None
	29	Self-limiting endothelial dysfunction/42	0	None
		Median	10 ± 20.24
Positive control—treatment-naive	1.1	Female 66, T2 lobular carcinoma, pleomorphic and solid variant, moderate diff. Hormone-positive phenotype pre-surgery sample	15	17
	1.2	Post-surgery sample	19	2
	5.1	Female 37, T2 moderately diff. invasive ductal carcinoma, triple negative phenotype/post-surgery sample	4	21
	7	Female 69, T1 high diff. invasive ductal carcinoma, hormone positive, post-surgery sample	8	1
	9.1	Female 49, T2 moderately diff. invasive ductal carcinoma, hormone positive, Her2+ phenotype, post-surgery sample	15	0
	12	Female 39, T2 moderate diff. invasive ductal carcinoma, hormone-positive phenotype, post-surgery sample	2	0
	8	Female 66, T1 moderately poor diff. invasive ductal carcinoma, hormone-positive phenotype, follow-up sample 6 months, no adjuvant treatment	7	0
	26	Female, 62, T2 invasive ductal carcinoma, LN involvement 1 in 12, hormone positive, Her2 10% phenotype	9	0
	27	Female 63, local recurrence patient 15 years, T2	0	7
		Median	8 ± 6.44
Positive control cohort—treatment mid-term	1.3	Mid-term	9	0
	5.2	Mid-term	11	11
	9.2	Mid-term	19	0
		Median	11 ± 5.29
Positive control—completion	1.4	Completion	8	0
	5.3	Completion	10	1
	9.3	Completion	17	4
Sum		Median	10 ± 4.73